ClinicalTrials.gg
Active, not recruitingNCT07270783Updated Oct 13, 2026

Healthy Volunteer Study

A Phase 1 interventional study of D-2570 and Placebo in Healthy Volunteer, sponsored by InventisBio Co., Ltd. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Other

Updated Oct 13, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.

Read the detailed description

Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer subjects meeting eligibility criteria

Exclusion criteria

Exclusion Criteria:

  • Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
  • Subjects with a history of drug and alcohol abuse
  • Subjects taking medications, over the counter or herbal remedies
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cohort 1 D-2570/Placebo

    Drug: D-2570 · Drug: Placebo

  • Experimental
    Cohort 2 D-2570/Placebo

    Drug: D-2570 · Drug: Placebo

  • Experimental
    Cohort 3 D-2570/Placebo

    Drug: D-2570 · Drug: Placebo

Interventions

  • DrugD-2570

    D-2570

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Incidence of adverse events

    Time frame: From Informed Consent through study completion, an average of 48 days

  2. Result of Pharmacokinetic endpoint

    Tmax

    Time frame: From Randomization through study completion, an average of 20 days

  3. Result of Pharmacokinetic endpoint

    Cmax

    Time frame: From Randomization through study completion, an average of 20 days

  4. Result of Pharmacokinetic endpoint

    t1/2

    Time frame: From Randomization through study completion, an average of 20 days

  5. Result of Pharmacokinetic endpoint

    MRT

    Time frame: From Randomization through study completion, an average of 20 days

  6. Result of Pharmacokinetic endpoint

    AUC0-∞

    Time frame: From Randomization through study completion, an average of 20 days.

  7. Result of Pharmacokinetic endpoint

    AUC0-t

    Time frame: From Randomization through study completion, an average of 20 days

  8. Result of Pharmacokinetic endpoint

    CL/F

    Time frame: From Randomization through study completion, an average of 20 days

  9. Result of Pharmacokinetic endpoint

    Vz/F

    Time frame: From Randomization through study completion, an average of 20 days

07

Study locations

1 site
  • Pharmaron
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2025 to primary completion in Jun 2026, 6 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Dec 8, 2025
StartActual
Dec 4, 2025
Primary completionActual
Jun 25, 2026
CompletionEst.
Nov 2026was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Sep 2026→Nov 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Study completion Sep 2026→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07270783
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Dec 4, 2025
Primary completion
Jun 25, 2026
Completion
Nov 2026 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-2570

Start the discussion